Status:
RECRUITING
Sentinel Node Mapping in High Risk Endometrial Cancer
Lead Sponsor:
AC Camargo Cancer Center
Conditions:
Endometrial Cancer
Lymph Node Metastases
Eligibility:
FEMALE
18-75 years
Phase:
NA
Brief Summary
This study will evaluate the role of systematic lymphadenectomy after sentinel node (SLN) mapping in high risk endometrial cancer (high grade histologies or deep myometrial invasion). The participants...
Detailed Description
Although most patients with endometrial cancer present with early-stage disease, the standard treatment still includes systematic lymph node dissection for staging. Recently, SLN mapping has emerged a...
Eligibility Criteria
Inclusion
- High grade histologies (endometrioid grade 3, serous, clear cell and carcinosarcoma)
- Endometrioid grades 1 or 2 with myometrial invasion of ≥50%
- Endometrioid grades 1 or 2 with cervical invasion
- Clinically suitable to receive systematic lymphadenectomy
- Consent statement
Exclusion
- Previous hysterectomy in other institution
- Presence of extra-uterine disease (peritoneal, visceral or suspicious lymph node metastasis)
- Previous pelvic node dissection
Key Trial Info
Start Date :
December 22 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 20 2024
Estimated Enrollment :
178 Patients enrolled
Trial Details
Trial ID
NCT03366051
Start Date
December 22 2017
End Date
December 20 2024
Last Update
July 30 2024
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Erasto Gaertner
Curitiba, Paraná, Brazil
2
Hospital do Cancer de Barretos
Barretos, São Paulo, Brazil
3
AC Camargo Cancer Center
São Paulo, São Paulo, Brazil, 01509010
4
Albert Einstein Hospital
São Paulo, São Paulo, Brazil